Antibody specificity is of pivotal importance in clinical diagnosis, OriGene has developed UltraMAB™, a class of monoclonal antibodies of ultra specificity for such rigorous requirement.
Video below illustrates the importance of using UltraMAB™ in IHC-based clinical diagnosis. Nuclear protein ERCC1 was used as an example. ERCC1 is used as a biomarker to predict caner patient responsiveness to cisplatin chemotherapy, and OriGene discovered that the existing antibody against ERCC1 was not specific.
